GENFIT : GENFIT-SANOFI Collaboration: Second Milestone achieved with success

 GENFIT : GENFIT-SANOFI Collaboration: Second Milestone achieved with success

                         GENFIT-SANOFI Collaboration:
                    Second Milestone achieved with success

Lille (France),  Boston (Massachusetts,  United States),  January 22,  2013  - 
GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company  at 
the forefront  of  drug  discovery  and development,  focusing  on  the  early 
diagnosis  and  preventive   treatment  of   cardiometabolic  and   associated 
disorders, today  announces  the  demonstration of  the  activity  of  several 
chemical series,  selected as  part of  the second  approach of  its  research 
program with SANOFI.

The achievement of this second key milestone follows on from the first one  in 
April 2012, in the context of the research contract signed in March 2011 for a
period of three years, during which SANOFI and GENFIT are committed to working
together on the  discovery and  development of new  drug candidates  targeting 
several metabolic disorders.

With this demonstration, a second  scientific foundation stone is thus  placed 
for one of  the approaches  of this research  program targeting  mitochondrial 
dysfunction. These results confirm the hypothesis, formulated in early 2011 on
the basis of clinical observations, that the adaptation to stress of  cellular 
mechanisms regulating  energy production  offers  a therapeutic  potential  in 
numerous pathologies including metabolic diseases.  

In accordance with  the terms  of the  contract, whereby  SANOFI obtained  the 
exclusive worldwide rights to develop and commercialize the molecules  arising 
from the  research  collaboration,  GENFIT  has received  the  second  of  the 
milestone payments  included in  the  collaboration and  licensing  agreement. 
Depending on  the preclinical  and clinical  development, and  the  subsequent 
registration and commercialization  of resulting  products, the  total of  the 
milestone payments included in  the agreement could  reach $54.5 million  (€39 
million), in addition to royalties from future sales of products developed  by 
SANOFI and resulting from the collaboration.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development
of drug candidates in therapeutic  fields linked to cardiometabolic  disorders 
(prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases.).
GENFIT uses  a multi-pronged  approach based  on early  diagnosis,  preventive 
solutions,  and  therapeutic  treatments  and  advances  therapeutic  research 
programs, either independently or  in partnership with leading  pharmaceutical 
companies, including Sanofi, to address these major public health concerns and
their unmet medical needs.
GENFIT's research  programs  have resulted  in  the  creation of  a  rich  and 
diversified pipeline of  drug candidates at  different stages of  development, 
including GENFIT's lead  proprietary compound,  GFT505, that  is currently  in 
PhaseIIb. 
With facilities in  Lille, France, and  Cambridge, MA (USA),  the Company  has 
approximately 80 employees. GENFIT is a public company listed on the Alternext
trading market by Euronext(TM)  Paris (Alternext: ALGFT; ISIN:  FR0004163111). 
www.genfit.com

Contacts:
GENFIT
Jean-François Mouney - CEO & Chairman of the Management Board - Ph. +333 2016
4000
Milestones - Press Relations
Bruno Arabian Ph. +331 7544 8740 / +336 8788 4726 - barabian@milestones.fr

2013.01.22 PR GENFIT-SANOFI.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: GENFIT via Thomson Reuters ONE
HUG#1671955
 
Press spacebar to pause and continue. Press esc to stop.